Concurrent radio-chemotherapy in N2 non small cell lung cancer: Interim analysis

Pierluigi Granone, Stefano Margaritora, Alfredo Cesario, Pierluigi Bonatti, Domenico Galetta, Aurelio Picciocchi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: In recent years many authors have been focused on N2 non- small cell lung cancer patients to determine whether the rate of resectability and long term survival can be improved by a combined preoperative treatment, with significant results. Following these experiences, we planned an induction therapy trial to assess the impact on downstaging, resectability and survival of concurrent radio-chemotherapy on N2 non-small cell lung cancer patients. Methods: Between January 1990 and August 1995, 82 N2 non-small cell lung cancer patients (44 IIIA and 38 IIIB) received preoperative chemo-radiotherapy with a single cycle of Carboplatin (90 mg/m2 per day for days 1-4), concurrent with radiotherapy (daily radiation dose of 180 cGray for a total of 5040). After surgery, all patients received multi-drug chemotherapy with Carboplatin 300 mg/m2 per day on day 1 and VP-16 100 mg/m2 per day on days 1, 2 and 3, for a total of 6 monthly cycles. Patient with unresectable tumors underwent to this multi-drug chemotherapy, directly. Results: Two patients were excluded from the study. When the remaining 80 patients had a 'clinical' re-staging, 41 (51.3%) showed a major response, 36 (45%) had minimal or none response, and 3 (3.7%) had progression of disease. Forty-one patients were judged to be resectable, II staged IIIB, and 30 IIIA; 2 patients of the IIIB group refused surgery. Of the 39 operated cases, 37 were completely resected (resectability rate: 94.8%). We report one perioperative death due to respiratory failure and two major complications. The overall actuarial 5 year survival is 24.5%. Downstaging was observed in 22 patients (56.4%), with three patients (7.7%) having no evidence of tumor in the specimen, 16 (41%) having sterilization of all lymph nodes, and three (7.7%) having sterilization of mediastinal nodes but positive N1 nodes. The 5-year actuarial survival is 53% for patients who had complete resection and 0% for patients with no resection (P = 0.0000). Conclusions: The following conclusions are possible: preoperative radiotherapy and chemotherapy with Carboplatin is well tolerated by patients, does not increase postoperative complications and produces an high rate of response. There is an high resection rate for patients who respond to the therapy. Patients with major response who undergo complete surgical resection had statistically significant improved survival compared with patients whose disease was not resected.

Original languageEnglish
Pages (from-to)366-371
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Volume12
Issue number3
DOIs
Publication statusPublished - Sep 1997

Fingerprint

Radio
Non-Small Cell Lung Carcinoma
Drug Therapy
Carboplatin
Survival
Radiotherapy
Etoposide
Respiratory Insufficiency
Pharmaceutical Preparations
Disease Progression

Keywords

  • Induction therapy
  • Lung cancer
  • Radio-chemotherapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Concurrent radio-chemotherapy in N2 non small cell lung cancer : Interim analysis. / Granone, Pierluigi; Margaritora, Stefano; Cesario, Alfredo; Bonatti, Pierluigi; Galetta, Domenico; Picciocchi, Aurelio.

In: European Journal of Cardio-thoracic Surgery, Vol. 12, No. 3, 09.1997, p. 366-371.

Research output: Contribution to journalArticle

Granone, Pierluigi ; Margaritora, Stefano ; Cesario, Alfredo ; Bonatti, Pierluigi ; Galetta, Domenico ; Picciocchi, Aurelio. / Concurrent radio-chemotherapy in N2 non small cell lung cancer : Interim analysis. In: European Journal of Cardio-thoracic Surgery. 1997 ; Vol. 12, No. 3. pp. 366-371.
@article{3232e04ef90b4b6bbaf50f477d5a3386,
title = "Concurrent radio-chemotherapy in N2 non small cell lung cancer: Interim analysis",
abstract = "Objective: In recent years many authors have been focused on N2 non- small cell lung cancer patients to determine whether the rate of resectability and long term survival can be improved by a combined preoperative treatment, with significant results. Following these experiences, we planned an induction therapy trial to assess the impact on downstaging, resectability and survival of concurrent radio-chemotherapy on N2 non-small cell lung cancer patients. Methods: Between January 1990 and August 1995, 82 N2 non-small cell lung cancer patients (44 IIIA and 38 IIIB) received preoperative chemo-radiotherapy with a single cycle of Carboplatin (90 mg/m2 per day for days 1-4), concurrent with radiotherapy (daily radiation dose of 180 cGray for a total of 5040). After surgery, all patients received multi-drug chemotherapy with Carboplatin 300 mg/m2 per day on day 1 and VP-16 100 mg/m2 per day on days 1, 2 and 3, for a total of 6 monthly cycles. Patient with unresectable tumors underwent to this multi-drug chemotherapy, directly. Results: Two patients were excluded from the study. When the remaining 80 patients had a 'clinical' re-staging, 41 (51.3{\%}) showed a major response, 36 (45{\%}) had minimal or none response, and 3 (3.7{\%}) had progression of disease. Forty-one patients were judged to be resectable, II staged IIIB, and 30 IIIA; 2 patients of the IIIB group refused surgery. Of the 39 operated cases, 37 were completely resected (resectability rate: 94.8{\%}). We report one perioperative death due to respiratory failure and two major complications. The overall actuarial 5 year survival is 24.5{\%}. Downstaging was observed in 22 patients (56.4{\%}), with three patients (7.7{\%}) having no evidence of tumor in the specimen, 16 (41{\%}) having sterilization of all lymph nodes, and three (7.7{\%}) having sterilization of mediastinal nodes but positive N1 nodes. The 5-year actuarial survival is 53{\%} for patients who had complete resection and 0{\%} for patients with no resection (P = 0.0000). Conclusions: The following conclusions are possible: preoperative radiotherapy and chemotherapy with Carboplatin is well tolerated by patients, does not increase postoperative complications and produces an high rate of response. There is an high resection rate for patients who respond to the therapy. Patients with major response who undergo complete surgical resection had statistically significant improved survival compared with patients whose disease was not resected.",
keywords = "Induction therapy, Lung cancer, Radio-chemotherapy",
author = "Pierluigi Granone and Stefano Margaritora and Alfredo Cesario and Pierluigi Bonatti and Domenico Galetta and Aurelio Picciocchi",
year = "1997",
month = "9",
doi = "10.1016/S1010-7940(97)00206-6",
language = "English",
volume = "12",
pages = "366--371",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "3",

}

TY - JOUR

T1 - Concurrent radio-chemotherapy in N2 non small cell lung cancer

T2 - Interim analysis

AU - Granone, Pierluigi

AU - Margaritora, Stefano

AU - Cesario, Alfredo

AU - Bonatti, Pierluigi

AU - Galetta, Domenico

AU - Picciocchi, Aurelio

PY - 1997/9

Y1 - 1997/9

N2 - Objective: In recent years many authors have been focused on N2 non- small cell lung cancer patients to determine whether the rate of resectability and long term survival can be improved by a combined preoperative treatment, with significant results. Following these experiences, we planned an induction therapy trial to assess the impact on downstaging, resectability and survival of concurrent radio-chemotherapy on N2 non-small cell lung cancer patients. Methods: Between January 1990 and August 1995, 82 N2 non-small cell lung cancer patients (44 IIIA and 38 IIIB) received preoperative chemo-radiotherapy with a single cycle of Carboplatin (90 mg/m2 per day for days 1-4), concurrent with radiotherapy (daily radiation dose of 180 cGray for a total of 5040). After surgery, all patients received multi-drug chemotherapy with Carboplatin 300 mg/m2 per day on day 1 and VP-16 100 mg/m2 per day on days 1, 2 and 3, for a total of 6 monthly cycles. Patient with unresectable tumors underwent to this multi-drug chemotherapy, directly. Results: Two patients were excluded from the study. When the remaining 80 patients had a 'clinical' re-staging, 41 (51.3%) showed a major response, 36 (45%) had minimal or none response, and 3 (3.7%) had progression of disease. Forty-one patients were judged to be resectable, II staged IIIB, and 30 IIIA; 2 patients of the IIIB group refused surgery. Of the 39 operated cases, 37 were completely resected (resectability rate: 94.8%). We report one perioperative death due to respiratory failure and two major complications. The overall actuarial 5 year survival is 24.5%. Downstaging was observed in 22 patients (56.4%), with three patients (7.7%) having no evidence of tumor in the specimen, 16 (41%) having sterilization of all lymph nodes, and three (7.7%) having sterilization of mediastinal nodes but positive N1 nodes. The 5-year actuarial survival is 53% for patients who had complete resection and 0% for patients with no resection (P = 0.0000). Conclusions: The following conclusions are possible: preoperative radiotherapy and chemotherapy with Carboplatin is well tolerated by patients, does not increase postoperative complications and produces an high rate of response. There is an high resection rate for patients who respond to the therapy. Patients with major response who undergo complete surgical resection had statistically significant improved survival compared with patients whose disease was not resected.

AB - Objective: In recent years many authors have been focused on N2 non- small cell lung cancer patients to determine whether the rate of resectability and long term survival can be improved by a combined preoperative treatment, with significant results. Following these experiences, we planned an induction therapy trial to assess the impact on downstaging, resectability and survival of concurrent radio-chemotherapy on N2 non-small cell lung cancer patients. Methods: Between January 1990 and August 1995, 82 N2 non-small cell lung cancer patients (44 IIIA and 38 IIIB) received preoperative chemo-radiotherapy with a single cycle of Carboplatin (90 mg/m2 per day for days 1-4), concurrent with radiotherapy (daily radiation dose of 180 cGray for a total of 5040). After surgery, all patients received multi-drug chemotherapy with Carboplatin 300 mg/m2 per day on day 1 and VP-16 100 mg/m2 per day on days 1, 2 and 3, for a total of 6 monthly cycles. Patient with unresectable tumors underwent to this multi-drug chemotherapy, directly. Results: Two patients were excluded from the study. When the remaining 80 patients had a 'clinical' re-staging, 41 (51.3%) showed a major response, 36 (45%) had minimal or none response, and 3 (3.7%) had progression of disease. Forty-one patients were judged to be resectable, II staged IIIB, and 30 IIIA; 2 patients of the IIIB group refused surgery. Of the 39 operated cases, 37 were completely resected (resectability rate: 94.8%). We report one perioperative death due to respiratory failure and two major complications. The overall actuarial 5 year survival is 24.5%. Downstaging was observed in 22 patients (56.4%), with three patients (7.7%) having no evidence of tumor in the specimen, 16 (41%) having sterilization of all lymph nodes, and three (7.7%) having sterilization of mediastinal nodes but positive N1 nodes. The 5-year actuarial survival is 53% for patients who had complete resection and 0% for patients with no resection (P = 0.0000). Conclusions: The following conclusions are possible: preoperative radiotherapy and chemotherapy with Carboplatin is well tolerated by patients, does not increase postoperative complications and produces an high rate of response. There is an high resection rate for patients who respond to the therapy. Patients with major response who undergo complete surgical resection had statistically significant improved survival compared with patients whose disease was not resected.

KW - Induction therapy

KW - Lung cancer

KW - Radio-chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0030883471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030883471&partnerID=8YFLogxK

U2 - 10.1016/S1010-7940(97)00206-6

DO - 10.1016/S1010-7940(97)00206-6

M3 - Article

C2 - 9332913

AN - SCOPUS:0030883471

VL - 12

SP - 366

EP - 371

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 3

ER -